Comprehensive Management of Recurrent Serous Cystadenocarcinoma of the Ovary

Disease Overview: Serous Cystadenocarcinoma of the Ovary

Serous cystadenocarcinoma is the most common histological subtype of epithelial ovarian cancer. Because its early symptoms—such as bloating, pelvic pain, or changes in bowel habits—are often vague, it is frequently diagnosed at an advanced stage after the disease has spread throughout the peritoneal cavity. The standard of care generally involves a multipronged approach: surgical cytoreduction (debulking) to remove as much visible tumor as possible, paired with platinum-based chemotherapy. Advances in oncology have also introduced targeted maintenance therapies, including angiogenesis inhibitors (like bevacizumab) and PARP inhibitors (like olaparib), which aim to significantly delay disease recurrence. For patients who do experience a recurrence, specialized and aggressive interventions like secondary cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) can be highly effective in extending disease-free survival.

Initial Presentation and Primary Treatment

A 50-year-old female patient presented with carcinoma of the ovary, managed as serous cystadenocarcinoma. In 2019, her treatment protocol began with neoadjuvant chemotherapy to shrink the tumor burden prior to surgical intervention. She subsequently underwent primary cytoreductive surgery, which necessitated a right hemicolectomy to adequately address the extent of the disease. Following her surgical recovery, she completed her chemotherapy regimen and was transitioned to maintenance therapy utilizing a combination of bevacizumab and olaparib.

Disease Recurrence and Advanced Intervention

The patient remained monitored until 2023, when she unfortunately experienced a recurrence of the ovarian disease. To aggressively manage the recurrent cancer, the surgical oncology team opted for a secondary cytoreductive surgery. This procedure was paired with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a specialized technique that delivers highly concentrated, heated chemotherapy directly to the abdomen during surgery to destroy microscopic cancer cells.

Post-Operative Adjuvant Therapy and Current Status

Following the successful secondary cytoreduction and HIPEC procedure, the patient received an additional six cycles of chemotherapy consisting of paclitaxel and carboplatin. Upon completion of these cycles, she was placed on maintenance therapy with bevacizumab. It has now been two years since her secondary treatment, and the patient is currently doing well and remains completely disease-free.